Eli Lilly and Company (NYSE:LLY) has announced that the FDA has approved Jardiance (empagliflozin) 10 mg to lower the risk of cardiovascular death and hospitalization in adults with heart failure.
Lilly developed the drug, an SGLT2 inhibitor, in collaboration with Boehringer Ingelheim.
Jardiance is contraindicated in adults with type 1 diabetes, given its potential to elevate the risk of ketoacidosis in such patients.
It is also contraindicated in patients who are hypersensitive to empagliflozin or the excipients in Jardiance.
FDA first approved Jardiance as a treatment for type 2 diabetes in 2014.
In 2016, it won an indication for reducing the risk of cardiovascular death in adults with type 2 diabetes.
Lilly also notes that the drug is not recommended for improving glycemic control in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) under 30 mL/min/1.73 m2.
The company notes that the treatment …